AQbD Symposium 2024
Impact of Q14/Q2 on LC Procedures
Analytical Quality by Design (AQbD) is a science and risk-based approach to analytical procedure development that “starts with the end in mind”.
The recently adopted quality guidelines Q14 and Q2(R2) leverage AQbD principles. What does that mean for the Pharma LC lab? We are joined by industry thought leaders for an engaging discussion that will encompass strategies and case studies.
Each session will feature a panel of forward thinking leaders on the topic who will present their recent work and participate in a round table discussion.
Learning Objectives
- Understand opportunities and barriers related to the implementation of Q14
- Learn about analytical development strategies for every phase of clinical development
- Explore case studies applying Q14 to today’s analytical challenges
- Engage with pharma industry thought leaders
Session 1: Analytical LC Method Strategies in the Q14 Era
Tuesday, December 3, 2024 | Time: 10:00am ET | 3:00pm GMT | 4:00pm CET
With the Q14 and Q2(R2) guidelines now adopted by FDA and EMA, there is an opportunity to rethink strategies around analytical LC procedure development. Platform analytical procedures, phase-appropriate approaches, future proofing procedures for robustness, sustainability and user-friendliness are top-of-mind topics. Our panelists will discuss opportunities and barriers in the implementation of Q14.